[Skip to Navigation]
August 9, 1993

Comparison of Clinical Symptoms of Human Immunodeficiency Virus Disease Between Intravenous Drug Users and Homosexual Men

Author Affiliations

From the Infectious Disease Program, Department of Epidemiology, The Johns Hopkins School of Hygiene and Public Health, Baltimore, Md.

Arch Intern Med. 1993;153(15):1806-1812. doi:10.1001/archinte.1993.00410150094009

Background:  To compare the prevalence of human immunodeficiency virus (HIV)—related clinical symptoms among male intravenous drug users and homosexual men stratified by HIV serostatus and CD4 cell levels.

Methods:  A cross-sectional sample using concurrent longitudinal studies of the natural history of HIV-1 infection among intravenous drug users (N=539) and homosexual men (N=932) was recruited in Baltimore, Md. Participants were administered a risk behavior interview and physical examination, and had hematologic tests evaluated in a similar calendar period.

Results:  Both risk groups demonstrated an inverse relationship between frequency of symptoms and CD4 cell count. Fever, night sweats, and lymphadenopathy were not evaluated because pilot data suggested a confounding association with drug injection. Among those with mild to moderate immune suppression, intravenous drug users were significantly more likely than homosexual men to experience fatigue, weight loss, diarrhea, and shortness of breath; to have oral candidiasis, palpable spleen, and lower mean weight on physical examination; and abnormal hematocrit, platelets, and total lymphocyte counts. However, participants in either risk group with CD4 cell levels below 0.2 ×109/L experienced similar frequency of all clinical symptoms. Self-reported oral candidiasis increased fourfold with HIV infection and was as likely in both groups at all CD4 cell levels. Duration and recency of intravenous drug use was not significantly associated with the higher frequency of most clinical symptoms.

Conclusion:  Social factors are an important consideration in evaluating the association between clinical symptoms and HIV immunosuppression. Except for oral candidiasis, there are limitations for the use of clinical symptoms as intermediate outcome measures for HIV infection among intravenous drug users.(Arch Intern Med. 1993;153:1806-1812)